Abstract
Post-stroke depression (PSD) is a biopsychosocial disorder that affects individuals who have suffered a stroke at any point. PSD has a 20 to 60 percent reported prevalence among stroke survivors. Its effects are usually adverse, can lead to disability, and may increase mortality if not managed or treated early. PSD is linked to several other medical conditions, including anxiety, hyper-locomotor activity, and poor functional recovery. Despite significant awareness of its adverse impacts, understanding the pathogenesis of PSD has proved challenging. The exact pathophysiology of PSD is unknown, yet its complexity has been definitively shown, involving mechanisms such as dysfunction of monoamine, the glutamatergic systems, the gut-brain axis, and neuroinflammation. The current effectiveness of PSD treatment is about 30–40 percent of all cases. In this review, we examined different pathophysiological mechanisms and current pharmacological and non-pharmacological approaches for the treatment of PSD.
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference206 articles.
1. Post-stroke depression: A review;Robinson;Am. J. Psychiatry,2016
2. Ambrosi, P.B., Ahmad, R., Abdullahi, A., and Agrawal, A. (2020). New Insight into Cerebrovascular Diseases: An Updated Comprehensive Review, IntechOpen.
3. Canadian stroke best practice recommendations: Mood, cognition and fatigue following stroke, update 2019;Lindsay;Int. J. Stroke,2020
4. Monoamine neurotransmitters and fibroblast growth factor-2 in the brains of rats with post-stroke depression;Ji;Exp. Ther. Med.,2014
5. Post stroke depression: Clinics, etiopathogenesis and therapeutics;Pedroso;Arch. Clin. Psychiatry,2015
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献